Biowaived Ltd CSO Mark McAllister published an article on the role of biopharmaceutics risk assessments, biopredictive testing, and evolving regulatory expectations in drug product development in Pharma Services Hub.
Public source
Publisher name
Public post
Our CSO, Mark McAllister, shares his insights on the role of biopharmaceutics risk assessments, biopredictive testing and evolving regulatory expectations in drug produc…
Company
Biowaived Ltd
Biopharmaceutics Experts
- Industry
- Research Services
- Location
- Sandwich, GB
- Company size
- 11–50 employees
About Biowaived Ltd
BioWaived Ltd. is a contract research organisation focused on delivering biopharmaceutics and dissolution strategies and tailored work packages to support drug development. Our services include consultancy and laboratory based experimental support for biopharmaceutical risk assessment, optimising formulation performance for relative bioavailability & bioequivalence studies and our product performance-led approach to dissolution method development.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Quotient Sciences
Quotient Sciences published a Q&A by Iain Shaw discussing how human ADME study design is changing in practice following the FDA's 2024 guidance.
Research & Knowledge
Lovelace Biomedical
Lovelace Biomedical published a blog post titled 'The goal is not the largest possible dataset. It is the information needed to support the next meaningful decision' that highlights the importance of fast, clean answers in drug development.
Research & Knowledge
CenPharma
CenPharma published an article breaking down what a phase appropriate approach looks like, how quality systems should mature alongside a product, and how to avoid accumulating quality debt.
Research & Knowledge
Veeda Lifesciences
Veeda Lifesciences published an article exploring glucose clamp studies in biosimilar and generic insulin development, covering protocol optimization, study quality, PK/PD data reliability, regulatory expectations, best practices, emerging trends, and an integrated clinical, bioanalytical, and biometrics approach.
Research & Knowledge
53Biologics